Verana Health announced it has merged with COTA, combining real-world data (RWD) assets and AI-driven curation technology to expand the scale and clinical depth of its offerings for biopharma customers across oncology and other specialties.
Verana said the combined company will serve 17 of the top 20 global biopharma companies and will have access to more than 95 million patients and over 20,000 contributing clinicians, including an expanded network of more than 30 academic medical centers. The merger is expected to significantly increase Verana’s oncology footprint, with access to more than 10 million oncology patients, while adding high-fidelity oncology datasets and analytics from COTA to Verana’s existing focus areas in ophthalmology, urology, and neurology.
The company said the combined portfolio will support life sciences customers across clinical trials, regulatory submissions, health economics and outcomes research, and market access, while continuing to provide advisory services for clinicians’ MIPS submissions. Verana said the integration of COTA’s oncology datasets will allow faster processing of real-world data from academic centers and enable delivery of ready-to-analyze datasets to research teams.
As part of the merger, Verana said existing institutional investors and industry veteran investors committed an additional $52 million in equity investment, though financial terms of the transaction were not disclosed. Wilson Sonsini Goodrich & Rosati served as legal counsel to Verana Health, BofA Securities provided exclusive financial services, and Morse Law served as legal counsel to COTA.
KEY QUOTES:
“We’re very excited to welcome COTA as we significantly broaden and amplify our capabilities for the life sciences community. This is a unique opportunity to better serve organizations with advanced curation technology and real-world insights across multiple specialty therapeutic areas. This combination raises the bar for clinical expertise, data quality, validation, and transparency, so our partners can generate evidence with the utmost confidence.”
Sujay Jadhav, CEO, Verana Health
“We’re pleased to join with Verana Health and bring together two exceptional and unique companies delivering real-world data solutions for the life sciences industry. Our shared commitment to advancing high-quality data and service offerings will help support the discovery of new treatment protocols and ultimately transform patient care.”
CK Wang, M.D., CEO, COTA
